AbCellera Biologics (ABCL) Tax Provisions: 2020-2024
Historic Tax Provisions for AbCellera Biologics (ABCL) over the last 5 years, with Dec 2024 value amounting to -$37.5 million.
- AbCellera Biologics' Tax Provisions rose 4.41% to -$1.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$27.6 million, marking a year-over-year decrease of 134.29%. This contributed to the annual value of -$37.5 million for FY2024, which is 35.85% down from last year.
- According to the latest figures from FY2024, AbCellera Biologics' Tax Provisions is -$37.5 million, which was down 35.85% from -$27.6 million recorded in FY2023.
- In the past 5 years, AbCellera Biologics' Tax Provisions ranged from a high of $80.6 million in FY2022 and a low of -$37.5 million during FY2024.
- Over the past 3 years, AbCellera Biologics' median Tax Provisions value was -$27.6 million (recorded in 2023), while the average stood at $5.1 million.
- As far as peak fluctuations go, AbCellera Biologics' Tax Provisions surged by 68.79% in 2021, and later slumped by 134.29% in 2023.
- Over the past 5 years, AbCellera Biologics' Tax Provisions (Yearly) stood at $38.9 million in 2020, then soared by 68.79% to $65.7 million in 2021, then climbed by 22.68% to $80.6 million in 2022, then plummeted by 134.29% to -$27.6 million in 2023, then slumped by 35.85% to -$37.5 million in 2024.